Laurus Labs receives two approvals from USFDA.
Deepthi | Myequity news | Date : 11-03-2019 17:05:00 IST
Laurus Labs Ltd has recently received a final approval from United States Food and Drug Administration (US FDA) for Hydroxychloroquine Tablets 200 mg which is used for treatment of certain type of Malaria. This medication is also used, usually with other medications, to treat certain auto-immune diseases (lupus, rheumatoid arthritis) when other medications have not worked or cannot be used. Hydroxychloroquine Tabs 200 Mg is therapeutically equivalent to Plaquenil Tablets 200mg of Concordia Pharmaceuticals, Inc.
In another development, the Company also received a tentative approval for an ANDA for Abacavir, Dolutegravir, and Lamivudine, Tablets 600 mg/50 mg/300 mg from USFDA.
The products will be commercialized from Laurus’ manufacturing site located at Atchutapuram, Visakhapatnam.
About Laurus Labs Limited:
Laurus Labs is a leading research & development driven and fully integrated pharmaceutical company in India. The Company has grown consistently to become one of the leading manufacturers of Active Pharmaceutical Ingredients (APIs) for anti-retroviral (ARV) and Hepatitis C. Laurus also manufactures APIs in Oncology and other therapeutic areas.